Global Irritable Bowel Syndrome Treatment Market Research Report Research Report forecast 2023
Summary - A new market study, titled “Global Irritable Bowel
Syndrome Treatment Market Research Report Forecast to 2023” has been featured
on Wise Guy Reports.
Introduction
Irritable
bowel syndrome (IBS) is a global issue, with 5% to 15% of the total population
experiencing symptoms that would satisfy the definition of IBS. This condition
is characterized by stomach pain and distress with altered bowel habits in the
absence of any other mechanical, inflammatory, or biochemical clarification for
these symptoms. The growing prevalence of anxiety, strong drug pipeline, and
increasing prevalence of depression are expected to drive the market growth.
In a systematic review of the
global prevalence of IBS, in 2015 Lovell and Ford documented a collective
prevalence of 11% with all regions of the world anguishing from this disorder
at parallel rates. However, stringent government regulations and limited
patient satisfaction with IBS treatment provided by healthcare professionals
may hamper the growth of the market.
The global irritable bowel
syndrome treatment market is expected to reach a market value of USD 2,988.6
million by 2023 from USD 1,890.9 million in 2017 and is expected to register a
CAGR of 7.58% during the forecast period from 2018 to 2023. In 2016, the
Americas held the highest share of the market at 45%, followed by Europe and
Asia-Pacific with shares of 29% and 18%, respectively. Growing prevalence of
IBS worldwide is expected to increase the growth of the market during the
forecast period.
The global irritable bowel
syndrome treatment market is segmented into type, drug type, end user, and
region.
The global irritable bowel
syndrome treatment market, by type, is segmented into IBS-D, IBS-C, and IBS-M.
The global irritable bowel
syndrome treatment market, by drug type, is segmented into lubiprostone,
linaclotide, eluxadoline, rifaximlin, alosetron, and others.
By end user, the global irritable
bowel syndrome treatment market is segmented into hospitals, clinics, research
laboratories, and others.
Key Players
Abbott, Allergan Inc., Ardelyx,
Inc., Astellas Pharma, Inc., Ironwood Pharmaceuticals, Lexicon Pharmaceuticals,
Inc., Mallinckrodt, Nestle Health Science, Synergy Pharmaceuticals Inc., and
Valeant Pharmaceuticals International, Inc.
Study Objectives
• To provide a detailed analysis
of the market structure along with the forecast of various segments and
sub-segments of the irritable bowel syndrome treatment market
• To provide insights into factors
affecting the market growth
• To analyze the global irritable
bowel syndrome treatment market based on various tools such as supply chain
analysis and Porter’s five force analysis
• To provide historical and
forecast revenue of market segments and sub-segments with respect to regions
and their respective key countries
• To provide country-level
analysis of the market with respect to the current market size and future
perspective
• To provide country-level
analysis of the market for segments by type, drug type, end user, and region
• To provide strategic profiling
of key players in the market, comprehensively analyzing their core competencies
and drawing a competitive landscape for the market
• To track and analyze competitive
developments such as joint ventures, strategic alliances, mergers and
acquisitions, new product developments, and research and developments in the
irritable bowel syndrome treatment market
Target Audience
• Pharmaceutical Companies
• Contract Research Organizations
(CROs)
• Research and Development
(R&D) Companies
• Government Research Laboratories
Key Findings
• The global irritable bowel
syndrome treatment market is expected to reach USD 2,988.6 million by 2023 at a
CAGR of 7.58% from 2018 to 2023
• On the basis of type, the IBS-D
segment accounted for the largest market share at a CAGR of 8.31%
• On the basis of drug type, the
linaclotide segment accounted for the largest market share at a CAGR of 7.95%
• On the basis of end user, the
hospitals segment accounted for the largest market share at a CAGR of 8.04%
• The Americas is expected to hold
the largest share of the global irritable bowel syndrome treatment market at a
CAGR of 8.69% by 2023
• Europe is the second largest
market, which is expected to register a CAGR of 7.31% by 2023
Regional Analysis
• Americas
o North America
US
Canada
o South America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa
FOR MORE DETAILS: https://www.wiseguyreports.com/reports/3977552-global-irritable-bowel-syndrome-treatment-market-research-report-forecast-to-2023
About Us :
Wise Guy Reports is part of the
Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive
statistical surveying, market research reports, analysis & forecast data
for industries and governments around the globe.
Contact
Us:
NORAH
TRENT
Ph: +162-825-80070
(US)
Ph: +44 203 500 2763
(UK)
Comments
Post a Comment